Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib. Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine ki...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Smith, Catherine C., Lasater, Elisabeth A., Zhu, Xiaotian, Lin, Kimberly C., Stewart, Whitney K., Damon, Lauren E., Salerno, Sara, Shah, Neil P.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2013
Teme:
Myeloid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3630831/
https://ncbi.nlm.nih.gov/pubmed/23430109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-442871
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki